Merck & Co names former CDC boss Julie Gerberding president of its $5 billion vaccines business
US drug giant Merck & Co has announced the appointment of former Centers for Disease Control and Prevention (CDC) director Julie Gerberding as president of Merck Vaccines, effective January 25, 2010. Merck's former vaccines chief, Margaret McGlynn, retired November 1 after having headed the vaccine business since 2005.
Dr Gerberding was director of the CDC from 2002 to 2009, stepping down on the inauguration of President Barack Obama early this year. During her tenure, she led the agency during more than 40 emergency response initiatives for health crises including anthrax bioterrorism, food-borne disease outbreaks, and natural disasters, and advised governments around the world on urgent public health issues such as SARS, AIDS and obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze